Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. Hill JA, et al. Among authors: sharon e. medRxiv [Preprint]. 2024 Jan 25:2024.01.24.24301058. doi: 10.1101/2024.01.24.24301058. medRxiv. 2024. Update in: Clin Infect Dis. 2024 Aug 16;79(2):542-554. doi: 10.1093/cid/ciae291 PMID: 38343800 Free PMC article. Updated. Preprint.
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. Hill JA, et al. Among authors: sharon e. Clin Infect Dis. 2024 Aug 16;79(2):542-554. doi: 10.1093/cid/ciae291. Clin Infect Dis. 2024. PMID: 38801746
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.
Othman T, Frankel P, Allen P, Popplewell LL, Shouse G, Siddiqi T, Danilov AV, Ruel N, Daniels S, Peters L, Khoo S, Rosen ST, Sharon E, Villalona-Calero M, Ruel C, Tuscano J, Herrera AF. Othman T, et al. Among authors: sharon e. Haematologica. 2025 Jan 1;110(1):142-152. doi: 10.3324/haematol.2024.285185. Haematologica. 2025. PMID: 39021209 Free PMC article. Clinical Trial.
Exacerbation of CMV and Nontuberculous Mycobacterial Infections Following PD-1 Blockade for HIV-Associated Kaposi Sarcoma.
Anidi IU, Sakai S, Brooks K, Fling SP, Wagner MJ, Lurain K, Lindestam Arlehamn CS, Sette A, Knox KS, Brenchley JM, Uldrick TS, Sharon E, Barber DL. Anidi IU, et al. Among authors: sharon e. Open Forum Infect Dis. 2024 Mar 31;11(5):ofae183. doi: 10.1093/ofid/ofae183. eCollection 2024 May. Open Forum Infect Dis. 2024. PMID: 38680611 Free PMC article. Clinical Trial.
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.
Mayadev J, Zamarin D, Deng W, Lankes HA, Pesci G, Kim H, Chino JP, Banbury B, Sherry N, Sharon E, Ghamande SA, Ferguson C, Mell L, Holman L, Mathews C, O'Malley D, Olawaiye A, Hopp E, Leath C 3rd, Copeland L, Mannel R, O'Cearbhaill R, Aghajanian C, Schilder RJ. Mayadev J, et al. Among authors: sharon e. Nat Commun. 2025 Jan 9;16(1):553. doi: 10.1038/s41467-024-55200-2. Nat Commun. 2025. PMID: 39788967 Free PMC article. Clinical Trial.
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).
Chae YK, Othus M, Patel SP, Gerber DE, Tanvetyanon T, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. Chae YK, et al. Among authors: sharon e. Ther Adv Med Oncol. 2024 Nov 22;16:17588359241293401. doi: 10.1177/17588359241293401. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39583952 Free PMC article.
A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer.
Sweis RF, Chatta GS, Jain RK, Moon H, Delacroix SE, Fang A, D'Amico L, Kask AS, Cheever MA, Fling S, Sharon E, Lacroix A, Kaiser JC, Pachynski RK, Yu EY. Sweis RF, et al. Among authors: sharon e. Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1728. Online ahead of print. Clin Cancer Res. 2024. PMID: 39576210
365 results